Treatment of follicular lymphoma: current status

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Johnson P W, Rohatiner A Z, Whelan J S, Price C G, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies A J, Matthews J, Calaminici M, Norton A J, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 2426–2433
   PubMed Web of Science ®Google Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• O'Brien M E, Easterbrook P, Powell J, Blackledge G R, Jones L, MacLennan I C, et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med 1991; 80: 651–660
   PubMedGoogle Scholar
• Portlock C S, Rosenberg S A. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 10–13
   PubMed Web of Science ®Google Scholar
• Ardeshna K M, Smith P, Norton A, Hancock B W, Hoskin P J, MacLennan K A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe d'etude des lymphomes folliculaires. Groupe d'etude des lymphomes de l'adulte. J Clin Oncol 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Young R C, Longo D L, Glatstein E, Ihde D C, Jaffe E S, DeVita V T, Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25: 11–16
   PubMed Web of Science ®Google Scholar
• Swenson W T, Wooldridge J E, Lynch C F, Forman-Hoffman V L, Chrischilles E, Link B K. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule. Blood 2004; 103: 4416–4123
   PubMed Web of Science ®Google Scholar
• Foran J M, Gupta R K, Cunningham D, Popescu R A, Goldstone A H, Sweetenham J W, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81–88
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13: 928–943
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris HA I II, Scullin D C, Jr, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Davis T A, White C A, Grillo-López A J, Velásquez W S, Link B, Maloney D G, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-López A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Overman M J, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, et al. The addition of rituximab to CHOP chemotherapy improves response rate, failure-free survival and overall survival for follicular grade 3 lymphoma compared to CHOP alone. Blood 2007; 110: 1289, (abstract)
   Google Scholar
• Hainsworth J D, Litchy S, Morrissey L H, Andrews M B, Grimaldi M, McCarty M, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2005; 23: 1500–1506
   PubMed Web of Science ®Google Scholar
• Economopoulos T, Fountzilas G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodoulou C, et al. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J 2003; 4: 110–115
   Google Scholar
• Savage D G, Cohen N S, Hesdorffer C S, Heitjan D, Oster M W, Garrett T J, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 477–481
   PubMed Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007; 110: 121–128
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003; 123: 271–277
   PubMed Web of Science ®Google Scholar
• Rummel M J, Atta J, Welslau M, Kofahl-Krause D, von Gruenhagen U, Schalk K, et al. Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: long-term follow-up of a phase II study. J Clin Oncol 2007; 25: 8034, (abstract)
   Google Scholar
• Suzuki Y, Danbara M, Hayama M, Togano T, Ohsaka M, Miyazaki K, et al. Phase II: combination of cladribine, cyclophosphamide, mitoxantrone, rituximab (R-CCM) in patients with relapsed and refractory follicular and mantle cell lymphoma, results of a prospective study at Kitasato University. J Clin Oncol 2007; 25: 18542, (abstract)
   Google Scholar
• Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Böck H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar
• Cheung M C, Berinstein N L, Pennell N, Hicks L K, Imrie K R, Piliotis E, et al. Prolonged clinical and molecular remissions following high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and rituximab and interferon-alpha maintenance for relapsed high-risk follicular lymphoma. Blood 2007; 110: 1902, (abstract)
   Google Scholar
• Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Long-term follow-up of the randomized GITMO/IIL trial comparing CHOP-rituximab vs. high-dose therapy rituximab (R-HDS) in high risk follicular lymphoma (FL): updated results suggest the use of R-HDS as salvage treatment. Blood 2007; 110: 20, (abstract)
   Google Scholar
• Friedberg J W, Huang J, Dillon H, Farber C, Feliciano S, Hainsworth J, et al. Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National lymphocare study (NLCS). J Clin Oncol 2006; 24: 7527, (abstract)
   Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the groupe d'etude des lymphomes de l'adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol 2006; 24: 7508, (abstract)
   Google Scholar
• Primary Rituximab and Maintenance Study. ClinicalTrials. gov Identifier: NCT0014058 - [cited 2008 May 07], Available from http://www.clinicaltrials.gov
   Google Scholar
• Witzig T E, Vukov A M, Habermann T M, Geyer S, Kurtin P J, Friedenberg W R, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central cancer treatment group. J Clin Oncol 2005; 23: 1103–1108
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl cancer research network. J Clin Oncol 2005; 23: 1088–1095
   PubMed Web of Science ®Google Scholar
• Kahl B S. Eastern cooperative oncology group 4402: rituximab extended schedule or retreatment trial (RESORT). Clin Lymphoma Myeloma 2006; 6: 423–426
   PubMedGoogle Scholar
• Ghielmini M. Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematol Am Soc Hematol Educ Program 2005; 2005: 321–328
   Google Scholar
• Zelenetz A D, Abramson J S, Advani R H, Byrd J C, Czuczman M S, Damon L E, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma V3. 2007 - [cited 2008 May 12], Available from http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
   Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Marcus R, Solal-Celigny P, Imrie K, Catalano J V, Dmoszynska A, Raposo J C, et al. MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL). Blood 2006; 108: 481, (abstract)
   Google Scholar
• Salles G A, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi J-F, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 2007; 110: 792, (abstract)
   Web of Science ®Google Scholar
• Federico M, Bellei M, Pro B, Lopez-Guillermo A, Marcheselli L, Trneny M, et al. Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol 2007; 25: 8008, (abstract)
   Google Scholar
• Press O W, Unger J M, Braziel R M, Maloney D G, Miller T P, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143–4149
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Bischof-Delaloye A, Radford J A, Rohatiner A, Salles G, Van Hoof Achiel, et al. 90Y-Ibritumomab Tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 first-line indolent trial (FIT) in 414 Patients. Blood 2007; 110: 643, (abstract)
   Google Scholar
• Bischof-Delaloye A, Antonescu C, Hagenbeek A. Dosimetric analysis of 90Y-Ibritumomab tiuxetan (Zevalin®) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international phase 3 First-Line Indolent Trial (FIT). Blood 2007; 110: 3415, (abstract)
   Google Scholar
• Gondek K, Shah S, Bischof-Delaloye A, Rohatiner A, Salles G, Put Barbara, et al. Health-related quality of life in patients with advanced-stage follicular lymphoma receiving consolidation with 90Y-ibritumomab tiuxetan (Zevalin®) of first remission: results from the randomized phase 3 First-Line Indolent Trial (FIT). Blood 2007; 110: 3319, (abstract)
   Google Scholar
• Hochster H S, Weller E, Ryan T, Habermann T M, Gascoyne R, Frankel R, et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 2004; 22: 6502, (abstract)
   Google Scholar
• Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Passera R, et al. Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis. J Clin Oncol 2007; 25: 8006, (abstract)
   Google Scholar
• Vose J M, Wahl R L, Saleh M, Rohatiner A Z, Knox S J, Radford J A, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Saleh M, Vose J M, Younes A, Kaminski M S. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and Iodine I131 tositumomab (Bexxar). Blood 2002; 100: 1384, (abstract)
   Google Scholar
• Horning S J, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23: 712–719
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Wiseman G A, Gordon L I, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Witzig T E, Gordon L, Beck T, Fehrenbacher L, Kornmehl E, et al. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Proc Am Soc Clin Oncol 2002; 21: 51, (abstract)
   Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, Witzig T E, Spies S, Bartlett N L, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Fisher R I, Kaminski M S, Wahl R L, Knox S J, Zelenetz A D, Vose J M, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565–7573
   PubMed Web of Science ®Google Scholar
• Witzig T E, Molina A, Gordon L I, Emmanouilides C, Schilder R J, Flinn I W, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804–1810
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H E, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Vose J, Bierman P, Lynch J, Bociek G, Armitage J. Long-term outcomes of autologous stem cell transplantation for follicular non-hodgkin's lymphoma: effect of histologic grade. J Clin Oncol 2005; 23: 6567, (abstract)
   Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Straus D, Portlock C, Hamlin P, et al. Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience. Ann Oncol 2005; 16: 099, (abstract)
   Google Scholar
• de Vos S, Dakhil S, McLaughlin P, Saleh M, Belt R, Flowers C, et al. Bortezomib plus rituximab in patients with indolent non-hodgkin's lymphoma (NHL): a phase 2 study. Blood 2005; 106: 17, (abstract)
   Google Scholar
• Czuczman M S, Thall A, Witzig T E, Vose J M, Younes A, Emmanouilides C, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390–4398
   PubMed Web of Science ®Google Scholar
• Strauss S J, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani P L, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 3880–3886
   PubMed Web of Science ®Google Scholar